Jamshedpur Reporter

Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, and Others.

 Breaking News
  • No posts were found

Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, and Others.

December 07
22:20 2023
Bladder Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, and Others.

DelveInsight’s, “Bladder Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Bladder Cancer Pipeline Report

  • DelveInsight’s Bladder Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Bladder Cancer treatment.
  • The leading companies working in the Bladder Cancer Market include CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. Ltd, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, enGene, Inc., Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, Inc., BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and others.
  • Promising Bladder Cancer Pipeline therapies in the various stages of development include Hexaminolevulinate hydrochloride, CG0070, Pembrolizumab Injection, ADSTILADRIN, Enfortumab Vedotin, and others.
  • October 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials of Pembrolizumab and Enfortumab Vedotin. This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone.
  • October 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab and Bempegaldesleukin. The purpose of the study is to see if treatment with nivolumab plus bempegaldesleukin or nivolumab alone, before and after surgery to remove the bladder, is more effective than surgery alone in participants with high-risk urothelial cancer, including muscle-invasive bladder cancer who are not able to receive cisplatin chemotherapy. A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible.
  • October 2023 Ferring Pharmaceuticals announced a study of Phase 3 clinical trials for FE 999326. To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC. A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC).
  • October 2023: Janssen Research & Development LLC announced a study of Phase 3 clinical trials for TAR-200 and Cetrelimab. The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).  The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG.

 

Request a sample and discover the recent advances in Bladder Cancer Treatment Drugs @ Bladder Cancer Pipeline Outlook Report

 

In the Bladder Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Bladder Cancer Overview

Bladder cancer is a disease that usually begins in the cells that line the inside of the bladder. It typically affects people older than 70 and occurs more often in men. Bladder cancer is the fifth most common form of cancer overall and the fourth most common among men.

 

Find out more about Bladder Cancer Therapeutics Assessment @ Bladder Cancer Preclinical and Discovery Stage Products

 

Bladder Cancer Emerging Drugs Profile

  • CG0070: CG Oncology
  • N-803: ImmunityBio
  • UGN-102: UroGen
  • Trilaciclib: G1 Therapeutics

 

Bladder Cancer Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Bladder cancer therapies. The Bladder cancer companies which have their Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, CG Oncology.

 

DelveInsight’s Bladder Cancer pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Bladder Cancer Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Learn more about the emerging Bladder Cancer Pipeline Therapies @ Bladder Cancer Clinical Trials Assessment

 

Scope of the Bladder Cancer Pipeline Report

  • Coverage- Global
  • Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Bladder Cancer Companies- CG Oncology, ImmunityBio, UroGen, G1 Therapeutics, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co.,Ltd., Nektar Therapeutics, Hamlet Pharma AB, Asieris Pharmaceuticals, Wuhan Binhui Biotechnology, Pfizer, Taizhou Hanzhong biomedical co. Ltd, Hoffmann-La Roche, Protara Therapeutics, AstraZeneca, CicloMed LLC, enGene, Inc., Emtora Biosciences, Qilu Pharmaceutical Co., Ltd., Theralase Inc., Vaxiion Therapeutics, Janssen Research & Development, LLC, Seagen Inc., RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences, Lindis Biotech, Incyte Corporation, Eli Lilly and Company, Daiichi Sankyo, Nektar Therapeutics, Pieris Pharmaceuticals, Inc., Istari Oncology, Inc., BeiGene, Vyriad, Inc., Adlai Nortye Biopharma Co., Ltd., Kyowa Kirin, Inc., Infinity Pharmaceuticals, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Fusion Pharmaceuticals Inc., GI Innovation, Inc., SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, and others.
  • Bladder Cancer Pipeline therapies- Hexaminolevulinate hydrochloride, CG0070, Pembrolizumab Injection, ADSTILADRIN, Enfortumab Vedotin, and others.

 

Dive deep into rich insights for new drugs for Bladder Cancer Treatment, Visit @ Bladder Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Bladder cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Bladder cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. CG0070: CG Oncology
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Trilaciclib: G1 Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. MV-NIS: Vyriad
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. FEP 633: PRISM BioLab
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Bladder cancer Key Companies
  21. Bladder cancer Key Products
  22. Bladder cancer- Unmet Needs
  23. Bladder cancer- Market Drivers and Barriers
  24. Bladder cancer- Future Perspectives and Conclusion
  25. Bladder cancer Analyst Views
  26. Bladder cancer Key Companies
  27. Appendix

 

For further information on the Bladder Cancer Pipeline therapeutics, reach out to Bladder Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market